Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...
Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...
Demand for humanitarian assistance is growing and existing financial resources are inadequate to address all areas of need. As stewards of limited funds, we have a responsibility to make the most ...
This systematic review found that studies of case management interventions have adequate quality and, in many cases, show cost-effective or even cost-saving results. Results: A total of 29 studies ...
Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...
Intracoronary imaging to guide complex PCI cases is initially more expensive than angiographic guidance but grows to be more cost-effective over a lifetime given the lower associated medical costs and ...
A long-acting injectable to prevent HIV infection may be generating hope that a new era in the battle against AIDS is about to begin. But a newly published analysis suggested the medicine will not be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results